CARTERRA SHIPS ITS FIRST ULTRA BIOSENSOR PLATFORM AND FINISHES 2024 WITH DOUBLE-DIGIT GROWTH AND RECORD REVENUES

SALT LAKE CITY, Jan 8 (Bernama) -- Carterra Inc., the world leader in enabling high-throughput biology, announced today that it has sold and shipped its first Carterra Ultra™ biosensor platform. Announced in September 2024, the Ultra instrument provides a full complement of small and large molecule applications while reprising gold-standard SPR detection, high-throughput, and the minimal sample requirements of Carterra’s LSA and LSAXT systems.

The Ultra shipment was the capstone on a record year for Carterra revenues as well as exceptional, double-digit growth. “We understand that spending and investment in drug discovery technologies—especially capital equipment like ours—has been challenged the last couple of years,” observes Tim Germann, Carterra’s Chief Commercial Officer. “Even so, drug and vaccine discovery groups are focused more than ever on going faster and spending less money to bring life-saving therapies to market—that’s exactly what Carterra platforms enable.”